Maintenance therapy in ulcerative colitis and crohn’s disease

Journal of Clinical Gastroenterology

Volumn 20, Issue 2, 1995, Pages 117-122

  Sachar, David B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aminosalicylates; Antimetabolites; Corticosteroids; Crohn s disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIMETABOLITE; AZATHIOPRINE; CYCLOSPORIN; MERCAPTOPURINE;

ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMAN; METRONIDAZOLE;

EID: 0028932679     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/00004836-199503000-00009     Document Type: Article

References (102)

1. Misiewicz JJ, Lennard-Jones JE, Connell AM. Baron JH, Joncs FA. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8.
2. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973;14:93-6.
3. Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.
4. deDombal FT, Dew MJ, Hanauer SB, et al. Towards an optimal dosage of oral 5-ASA in ulcerative colitis. Gastroenterol Int 1992;5:155-61.
5. Sandberg-Gertzen H, Järnerot G, Draaz W. Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse-prevention properties. Gastroenterology 1986;90: 1024-30.
6. Ireland A, Jewell DP. Olsalazine in patients intolerant of SASP. Scand J Gastroenterol 1989;22:1038-40.
7. Green JRB, Swan CHJ, Rowlinson A, et al. Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6: 647-52.
8. Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J 1982;285: 1012.
9. Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. Br Med J 1983;287:413.
10. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988;94: 1383-9.
11. Mulder CJJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95:1449-53.
12. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1989;3: 183-91.
13. Bianchi Porro G, Ardizzone S, Fasoli R, Petrillo M, Desideri S. Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis [Abstract]. Gut 1989;30: A1467.
14. Gionchetti P, Campieri M, Belluzzi A, et al. Pentasa in maintenance treatment of ulcerative colitis [Letter]. Gastroenterology 1990;98:251.
15. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988;29:835-7.
16. Killerich S, Ladefoged K, Rennem T, et al. Prophylactic effects of olsalazine v. sulphasalazine during 12 months of maintenance treatment of ulcerative colitis. Gut 1992;33:252-5.
17. Rijk MCM, Van Lier HJJ, van Tongeren JHM. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol 1992;87:438-42.
18. McIntyre P, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis: a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988;2:237-43.
19. De Franchis R, Vecchi M, Carpinelli L, Meucci G, TorganoG. Comparison of the efficacy and safety of sulphasalazine and mesalazines in the maintenance treatment of ulcerative colitis: a meta-analysis. Eur J Gastroenterol Hepatol 1993;5: 505-10.
20. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
21. Courtney MG, Nunes DP. Bergin CF, et al. Randomized comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279-81.
22. Travis SPL, Tysk C, Järnerot G, Jewell DP. A dose-ranging study of olsalazine in ulcerative colitis. Gut 1992;33:546.
23. GiafferH, Holdsworth CD, Lennard-Jones JE, et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4G/day compared with 2G/day. Aliment Pharmacol Ther 1992;6:479-85.
24. Fockens P, Mulder CJJ, Ferwerda J, Tytgag GNJ, the Dutch Pentasa Study Group. Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram vs 3 gram oral mesalazine (Pentasa) [Abstract]. Gastroenterology 1993;104:A701.
25. Hanauer S, Powers B, Robinson M, et al. Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo [Abstract]. Gastroenterology 1994;106:A696.
26. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine vs sulfasalazine for maintenance therapy of ulcerative colitis [Abstract]. Gastroenterologv 1992; 102:A649.
27. Green JRB, Swan CHJ, Rowlinson A, et al. Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6: 647-52.
28. Sutherland LR, Martin F. 5-aminosalicylic acid enemas in the maintenance of remission in distal ulcerative colitis and proctitis. Can J Gastroenterol 1987; 1:3-6.
29. Biddle WL, Greenberger NJ, Swan JT, McPhee MS, Miner PB Jr. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;94:1075-9.
30. D’Arienzo A, Panarese A, D’Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo controlled clinical trial. Am J Gastroenterol 1990;85:1079-82.
31. D’Albasio G, Trallori G, Ghetti A, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990;33:394-7.
32. Marshall JK, Irvine EJ. Topical aminosalicylate (ASA) therapy for distal ulcerative colitis: a meta-analysis [Abstract], Gastroenterology 1994;106:A1037.
33. Sutherland LR. Prevention of relapse in ulcerative colitis using oral or topical 5-aminosalicylic acid therapy. Can J Gastroenterol 1993;7:232-6.
34. Miner P, Daly R, Nester T, et al. The effects of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis [Abstract]. Gastroenterology 1994; 106:A736.
35. Truelove SC. Treatment of ulcerative colitis with local hydro-cortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J 1958;2:1072-7.
36. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1959;i:387-94.
37. Kirsner JB, Palmer WL, Spencer JA, Bicks RO, Johnson CF. Corticotropin (ACTH) and the adrenal steroids in the management of ulcerative colitis: observations in 240 patients. Ann Intern Med 1959;50:891-927.
38. Lennard-Jones JE, Misiewicz JJ, Connell AM, Jones FA. Pred-nisolone as maintenance treatment for ulcerative colitis in remission. Lancet 1965;l:188-9.
39. Powell-Tuck J, Parkins RA. A controlled trial of alternate-day prednisolone as maintenance treatment of ulcerative colitis in remission. Digestion 1981;22:263-70.
40. McLeod AD, Fedorak RN, Friend DR, Tozer TN, Cui N. A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterology 1994;106:405-13.
41. Matzen P, the Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis: a randomized dose-response trial with prednisolone enemas as positive control. Scand J Gastroenterol 1991;26:1225-30.
42. Danielsson A, Löfberg R, Persson T, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992;27: 9-12.
43. Belluzi A, Campieri M, Miglioli M, et al. Evaluation of phlogistic pattern in “pouchitis” before and after treatment with budesonide [Abstract]. Gastroenterology 1992;102:A593.
44. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercapto-purine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-22.
45. Lobo AJ, Foster PN, Burke DA, et al. The role of azathio-prine in the management of ulcerative colitis. Dis Colon Rectum 1990;33:374-7.
46. Jewell DP, Campieri M, Järnerot G, Modigliani R, Rask-Madsen J. New therapeutic modalities for inflammatory bowel disease (Working Team Report). Gastroenterol Int 1993;6:1 -12.
47. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BrMedJ 1992;305:20-2.
48. George J, Pou R, Bodian C, Rubin P, Present D. 6-mercapto-purine is effective in chronic ulcerative colitis but how long do you use it? [Abstract]. Gastroenterology 1994;106:A686.
49. Present DH, Meltzer SJ, Krumholz WP, Wolke A, Korelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease: short term and long term toxicity. Ann Intern Med 1989;lll:641-9.
50. Kozarek RA, Patterson DJ, Gelfand MD, Ball TJ, Botoman VA. Long-term use of methotrexate in inflammatory bowel disease [Abstract]. Gastroenterology 1992; 102:A648.
51. Lichtiger S, Present DH. Preliminary report: cyclosporin in the treatment of severe active ulcerative colitis. Lancet 1990; 336:16-9.
52. Lichtiger S, Present DH. Cyclosporin in the treatment of severe ulcerative colitis [Abstract]. Gastroenterology 1992; 102:A653.
53. Lichitger S, Present DH, Kornbluth A, Hanauer S. Cyclosporin A in the treatment of severe, refractory ulcerative colitis: a double-blind placebo controlled trial [Abstract]. Gastroenterology 1993;104:A732.
54. Kornbluth A, Lichtiger S, Present D, Hanauer S. Long-term results of oral cyclosporine in patients with severe ulcerative colitis [Abstract]. Gastroenterology 1994;106:A714.
55. Schneider JH, Sternthal MB, Lichtiger S, Present D, Kornbluth A. Cyclosporin A therapy in patients with severe ulcerative colitis [Abstract]. Am J Gastroenterol 1991;86:1361.
56. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77:847-9.
57. Malchow H, Ewe K, Brandes JR, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
58. BaronJH, BennetPN, Lennard-Jones JE, et al. Sulphasalazine in asymptomatic Crohn’s disease: a multi-centre trial. Gut 1977;18:69-72.
59. Wenckert A, Kristensen M, Eklund AE, et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin(r)) in primarily resected patients with Crohn’s disease: a controlled double-blind trial. Scand J Gastroenterol 1978;13:161-7.
60. Bergman L, Krause U. Postoperative treatment with cortico-steroids and salazosulphapyridine (Salazopyrin(r)) after radical resection for Crohn’s disease. Scand J Gastroenterol 1976;11: 651-6.
61. Ewe K, Herfarth C, Malchow H, Jesdinsky JH. Postoperative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis. Digestion 1989;42:224-32.
62. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M, Italian IBD Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease. Gastroenterology 1992;103:363-8.
63. Gendre J-P, Mary J-Y, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. Gastroenterology 1993;104: 435-9.
64. McLeod R, Wolff BG, Steinhart AH, et al. Decreased recurrence of Crohn’s disease following surgical resection [Abstract]. Gastroenterology 1994;106:A733.
65. Caprilli R, Andreoli A, Capusso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of postoperative recurrence of Crohn’s disease. Aliment Pharmacol Ther 1994;8:35-43.
66. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn’s disease. Dig Dis Sci 1992;37:29-32.
67. Thomson ABR, the International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn’s disease. Aliment Pharmacol Ther 1990;4:55-64.
68. Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn’s disease recurrences after intestinal resection with Eudragit-L-coatcd 5-aminosalieylic acid: preliminary results of a one year double-blind placebo controlled study [Abstract]. Gastroemerology 1991;100:A208.
69. Florent C, Cortot A, Quandale P, et al. Placebo-controlled trial of Claversal(r) in the prevention of early endoscopie relapse after “curative” resection for Crohn’s disease [Abstract]. Gastroemerology 1992; 102: A623.
70. Howaldt S, Raedler A, Reinecker H-C, et al. Comparative trial of remission prophylaxis in quiescent Crohn’s disease with oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Can J Gastroenterol 1993;7:241-4.
71. Brcsci G, Petrucci A. Banti S. 5-Aminosalicylic acid in the prevention of Crohn’s disease in remission: a long-term study. Im J Clin Pharm Res 1991;ll:200-2.
72. Sutherland LR. 5-Aminosalicylatcs for prevention of recurrence in patients with Crohn’s disease: time for a reappraisal? [Editorial]. J Clin Gastroenterol 1991;13:5-7.
73. Bondesen S, Danish 5-ASA Group. Mesalazine (Pentasa) as prophylaxis in Crohn’s disease: a multicenter controlled trial Abstract. Scarni J Gastroenterol 1991;26(suppl 183):68.
74. Messori A. Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994;89:692-8.
75. Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn’s disease: a controlled trial. Gut 1978;19:606-10.
76. Bello C, Goldstein F, Thornton J. Alternate-day prednisolone treatment and treatment maintenance in Crohn’s disease. Am J Gastroenterol 1991;86:460-6.
77. Brignola C, Campieri M, Farruggia P, et al. The possible utility of steroids in the prevention of relapses of Crohn’s disease in remission. J Clin Gastroenterol 1988;10:631-4.
78. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842-5.
79. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Chrohn’s disease. N Engl J Med 1994;331:836-41.
80. Löfberg R. Rutgeerts P, Malchow H, et al. Budesonide CIR for maintenance of remission in ileocecal Crohn’s disease: a European multicenter placebo controlled trial for 12 months [Abstract]. Gastroemerology 1994;106:A722.
81. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993;88:1198-205.
82. O’Brien JJ, Bayless TM, Bay Less JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease. Gastro-enterology 1991;101:39-46.
83. Stark ME, Tremaine WJ. Maintenance of symptomatic remission in patients with Crohn’s disease. Mayo Clin Proc 1993;68:1183-90.
84. Willoughby JMT, Kumer PJ, Beckett J, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971; 2:944-7.
85. O’Donoghue DP, Dawson AM. Powell-Tuck J, Brown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathio-prine as maintenance treatment for Crohn’s disease. Lancet 1978;2:955-7.
86. Rosenberg JL, Levine B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis 1975; 20:721-6.
87. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroemerology 1990;99:1347-5l.
88. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343:1249-52.
89. Lémann M, Bonhomme P, Bitoun A, et al. Traitement de la maladie de Crohn par l’azathioprine ou la 6-mercaptopurine. Gastroenterol Clin Biol 1990;14:548-54.
90. Arora S, Katkov WN, Cooley J, et al. A double-blind randomized, placebo-controlled trial of methotrexate in Crohn’s disease [Abstract]. Gastroemerology 1992;102:A591.
91. Brynskov J, Freund L, Norby Rasmussen S, et al. Final report on a placebo-controlled, double-blind, randomized multicentre trial of cyclosporin treatment in active chronic Crohn’s disease. Scand J Gastroenterol 1991;26:689-95.
92. Lobo AJ, Juby LD, Rothwell J, Poole TW, Axon ATR. Long-term treatment of Crohn’s disease with cyclosporine: the effect of a very low dose on maintenance of remission. J Clin Gastroenterol 1991;13:42-5.
93. Feagan B, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 1994;330:1846-51.
94. Bicks RO, Groshart KD. The current status of T-lymphocyte apheresis (TLA) treatment of Crohn’s disease [Editorial], J Clin Gastroenterol 1989;11:136-8.
95. Lerebours E, GETAID. Controlled trial of the efficacy of lymphocyte apheresis in preventing relapse in Crohn’s disease patients [Abstract]. Gastroemerology 1991;100:A224.
96. Sutherland L, Singleton J, Sessions J, et al. Double-blind, placebo-controlled trial of metronidazole in Crohn’s disease. Gut 1991;32:1071-5.
97. Rutgeerts P, Peeters M, Hiele M, et al. A placebo controlled trial of metronidazole for recurrence prevention of Crohn’s disease after resection of the terminal ileum [Abstract]. Gastroemerology 1992;102:A688.
98. Bernstein CN, Shanahan F. Metronidazole in Crohn’s disease: What’s the score? [Selected summary]. Gastroemerology 1992; 102:1435-6.
99. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Anti-mycobacterial therapy in Crohn’s disease: results of a controlled double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-8.
100. Rutgeerts P, Geboes K, Vantrappen G, et al. Rifabutin and ethambutol do not help recurrent Crohn’s disease in the neo-terminal ileum. J Clin Gastroenterol 1992;15:24-8.
101. Fernández-Banares F, Cabré E, González-Huix F, Gassull MA. Enterai nutrition as primary therapy in Crohn’s disease. Gut 1994;suppl 1:555-9.
102. Sachar DB. Cyclosporine treatment for inflammatory bowel disease [Editoriali. N Engl J Med 1989;321:894-6.